Roche says new data for Ocrevus multiple sclerosis drug showed benefits
Send a link to a friend
 [April 04, 2022]
BERLIN (Reuters) - Roche Holding AG
on Monday said new data for its Ocrevus drug showed benefits for the
treatment of disability progression and cognitive decline in both
secondary progressive and primary progressive multiple sclerosis.
Three-quarters of patients with secondary progressive multiple sclerosis
(SPMS) and primary progressive MS (PPMS) achieved no evidence of
progression in a one-year interim analysis of consonance study, the
Swiss pharmaceutical company said.
[to top of second column]
|
The logo of Swiss drugmaker Roche is seen at its headquarters in
Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann
 Roche also said 70% of patients with
SPMS and PPMS demonstrated stable or improved cognition after one
year of Ocrevus treatment in consonance.
(Writing by Miranda Murray; Editing by Christopher Cushing)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
